XML 17 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Balance Sheets - USD ($)
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 57,632,693 $ 40,543,982
Short-term investments 105,357,277 53,075,974
Accounts receivable 7,333,059 2,804,207
Prepaid expenses and other current assets 917,257 797,973
Prepaid expenses from affiliated entity 610,652 1,382,375
Deferred tax asset 0 342,573
Total current assets 171,850,938 98,947,084
Fixed assets, net 7,306,695 4,583,204
Investment in affiliated entity - GeneOne 14,941,277 12,340,811
Investment in affiliated entity - PLS 5,045,915 0
Intangible assets, net 3,905,860 4,776,059
Goodwill 10,113,371 10,113,371
Common stock warrants 5,970 550,000
Other assets 670,833 474,568
Total assets 213,840,859 131,785,097
Current liabilities:    
Accounts payable and accrued expenses 13,064,899 6,383,170
Accounts payable and accrued expenses due to affiliated entity 165,047 28,407
Accrued clinical trial expenses 2,600,483 2,007,432
Common stock warrants 1,301,138 2,022,729
Deferred revenue 13,449,768 3,187,223
Deferred revenue from affiliated entity 504,442 394,791
Deferred rent 380,629 61,542
Total current liabilities 31,466,406 14,085,294
Deferred revenue, net of current portion 103,074 173,779
Deferred revenue from affiliated entity, net of current portion 677,371 836,694
Deferred rent, net of current portion 5,485,313 4,647,687
Deferred tax liabilities 175,642 504,049
Total liabilities $ 37,907,806 $ 20,247,503
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2015 and December 31, 2014 $ 0 $ 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2015 and December 31, 2014, issued and outstanding: 72,217,965 at December 31, 2015 and 60,741,082 at December 31, 2014 72,218 60,741
Additional paid-in capital 534,004,564 443,327,915
Accumulated deficit (361,097,896) (331,910,290)
Accumulated other comprehensive income (loss) 2,708,339 (251,390)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 175,687,225 111,226,976
Non-controlling interest 245,828 310,618
Total stockholders' equity 175,933,053 111,537,594
Total liabilities and stockholders’ equity $ 213,840,859 $ 131,785,097